

# Growth Factor Induction of Cripto-1 Shedding by Glycosylphosphatidylinositol-Phospholipase D and Enhancement of Endothelial Cell Migration<sup>\*§</sup>

Received for publication, March 29, 2007, and in revised form, August 21, 2007. Published, JBC Papers in Press, August 24, 2007, DOI 10.1074/jbc.M702713200

Kazuhide Watanabe<sup>†</sup>, Caterina Bianco<sup>†</sup>, Luigi Strizzi<sup>†</sup>, Shin Hamada<sup>†</sup>, Mario Mancino<sup>†</sup>, Veronique Bailly<sup>§</sup>, Wenjun Mo<sup>§</sup>, Dingyi Wen<sup>§</sup>, Konrad Miatkowski<sup>§</sup>, Monica Gonzales<sup>‡</sup>, Michele Sanicola<sup>§</sup>, Masaharu Seno<sup>¶</sup>, and David S. Salomon<sup>††</sup>

From the <sup>†</sup>Tumor Growth Factor Section, Mammary Biology & Tumorigenesis Laboratory, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, <sup>§</sup>Biogen Idec Inc., Cambridge, Massachusetts 02142, and the

<sup>¶</sup>Department of Medical and Bioengineering Science, Graduate School of Natural Science and Technology, Okayama University, Okayama 700-8530, Japan

Cripto-1 (CR-1) is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that has been shown to play an important role in embryogenesis and cellular transformation. CR-1 is reported to function as a membrane-bound co-receptor and as a soluble ligand. Although a number of studies implicate the role of CR-1 as a soluble ligand in tumor progression, it is unclear how transition from the membrane-bound to the soluble form is physiologically regulated and whether differences in biological activity exist between these forms. Here, we demonstrate that CR-1 protein is secreted from tumor cells into the conditioned medium after treatment with serum, epidermal growth factor, or lysophosphatidic acid, and this soluble form of CR-1 exhibits the ability to promote endothelial cell migration as a paracrine chemoattractant. On the other hand, membrane-bound CR-1 can stimulate endothelial cell sprouting through direct cell-cell interaction. Shedding of CR-1 occurs at the GPI-anchor site by the activity of GPI-phospholipase D (GPI-PLD), because CR-1 shedding was suppressed by siRNA knockdown of GPI-PLD and enhanced by overexpression of GPI-PLD. These findings describe a novel molecular mechanism of CR-1 shedding, which may contribute to endothelial cell migration and possibly tumor angiogenesis.

The Epidermal Growth Factor-Cripto-1/FRL-1/Cryptic (EGF-CFC)<sup>2</sup> family of genes, including mammalian *Cripto-1*

(*CR-1/Tdgf1*), has been shown to play an important role in vertebrate development and in tumor progression (1). EGF-CFC proteins are indispensable for early embryonic development, being involved in the formation of the primitive streak, patterning of the anterior/posterior axis, mesoendoderm formation, and establishment of left-right asymmetry (2). *CR-1* is an oncofetal gene, which is expressed during early developmental stages and is re-expressed in several types of human carcinomas (3). In fact, CR-1 protein is highly expressed in a number of human carcinomas, including breast (75–82%), colon (67–84%), and gastric cancer (33–47%), where it is being assessed as a tumor-specific target for immunotherapy (3, 4). Mice that overexpress a human CR-1 transgene selectively in mammary epithelium develop mammary hyperplasia and adenocarcinomas (5–7). Conversely, blockade of CR-1-mediated signaling suppresses tumor growth (4, 8, 9).

CR-1 functions through at least three different signaling pathways: 1) as a co-receptor for the transforming growth factor  $\beta$ -related proteins Nodal and growth and differentiation factors 1 and 3 (10–12), 2) as a ligand for glypican-1/c-Src/MAPK/PI3K-Akt signaling (13), and 3) as an inhibitor for activin/transforming growth factor  $\beta$  signaling (8, 14). Nodal requires EGF-CFC proteins as co-receptors to bind the activin type I receptors (activin-like kinases 4 and 7) and activin type II receptor (ActRII). Embryological defects in CR-1-null mice are lethal mainly due to a disruption of Nodal-dependent signaling (15). CR-1 can also function independently of Nodal as a ligand for glypican-1, which can activate a c-Src/MAPK/PI3K-Akt intracellular signaling pathway (3) and then promote cell proliferation, survival, migration, and invasion (5). Some of the oncogenic actions of CR-1, such as tumor angiogenesis, utilize this latter pathway (16).

EGF-CFC proteins contain several domains that include an N-terminal signal peptide, a variant EGF-like domain, a

\* This work was supported by National Institutes of Health Intramural Funding. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. S1–S3.

<sup>†</sup> To whom correspondence should be addressed: Tumor Growth Factor Section, Mammary Biology & Tumorigenesis Laboratory, Center for Cancer Research, NCI, National Institutes of Health, Bldg. 37, Rm. 1118B, 37 Convent Drive, Bethesda, MD 20892-4254. Tel.: 301-496-9536; Fax: 301-402-8656; E-mail: salomon@MAIL.nih.gov.

<sup>‡</sup> The abbreviations used are: EGF-CFC, epidermal growth factor-Cripto-1/FRL-1/Cryptic; ADAM, a disintegrin and metalloproteinase domain; CR-1, Cripto-1; CTxB, Cholera toxin B; DRMs, detergent-resistant microdomains; EGFR, EGF receptor; EV, empty vector; FBS, fetal bovine serum; GPI, glycosylphosphatidylinositol; GPI-PLD, GPI-phospholipase D; HRP, horseradish peroxidase; HUVEC, human umbilical vein epithelial cell; IL-6, interleu-

kin-6; LPA, lysophosphatidic acid; mAb, monoclonal antibody; MS, mass spectrometry; MS/MS, tandem mass spectrometry; PKC, protein kinase C; PLC $\gamma$ , phospholipase C  $\gamma$ ; PMA, phorbol 12-myristate 13-acetate; PNT, 1,10-phenanthroline; SRM, suramin; TFR, transferrin receptor; MES, 2-(N-morpholino)ethanesulfonic acid; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; DAPI, 4',6-diamidino-2-phenylindole; FACS, fluorescence-activated cell sorting; siRNA, small interference RNA; RT, reverse transcription.

## Shedding of Cripto-1

cysteine-rich CFC domain, and a glycosylphosphatidylinositol (GPI)-linkage signal at the C-terminus. CR-1 is tethered to the outer leaflet of the plasma membrane via a GPI anchor (17). Although the GPI anchoring enables CR-1 to act as a membrane-bound co-receptor, CR-1 can also be released as a soluble protein (18, 19). However, the endogenous regulatory mechanism controlling CR-1 shedding is largely unknown.

We have previously found that CR-1 is a potent endothelial chemoattractant *in vitro* and promotes tumor angiogenesis *in vivo* (16). To facilitate endothelial cell migration *in vivo*, CR-1 should be released from tumor cells to interact with surrounding endothelial cells. In this respect, a recent study has demonstrated that the plasma levels of CR-1 in breast and colon cancer patients were significantly higher than those of healthy controls (20), suggesting that CR-1 is released into plasma from tumor cells and that plasma CR-1 levels might serve as a surrogate tumor marker. Therefore, shedding of CR-1 is a key biological process in understanding the characteristics of CR-1 as a diagnostic and therapeutic target in cancer and in delineating the mechanism by which CR-1 can initiate angiogenesis. In the current study, we have evaluated the differential roles of membrane-bound and soluble forms of CR-1 in stimulating endothelial cells and delineated the mechanism of CR-1 shedding *in vitro*.

## EXPERIMENTAL PROCEDURES

**Cells**—HEK293T (293T), MDCK, COS7, and SW480 cells (ATCC, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). NTERA2/D1 cells (ATCC) were grown in Macoy's 5A medium with 15% FBS. Human umbilical vein endothelial cells (HUVECs) were cultured as described previously (16, 21). Human embryonic cells Per-C6 (Crucell, Leiden, The Netherlands) transfected with wild-type CR-1 were grown in Dulbecco's modified Eagle's medium containing 10 mM MgCl<sub>2</sub>, 0.5 mg/ml G418, and 10% FBS.

**Reagents**—Human CR-1 monoclonal antibodies (mAbs) (MAB2771 and FAB2772P) were obtained from R&D Systems (Minneapolis, MN) or developed as previously reported (B3F6) (8). Rabbit polyclonal anti-CR-1 antibody was previously described (20). Antibodies against total p42/44 MAPK, phospho-p42/44 MAPK, total Akt, phospho-Akt, and phospho-Smad2 were obtained from Cell Signaling (Danvers, MA), total Smad2 from Upstate (Chicago, IL),  $\beta$ -actin from Sigma-Aldrich, and transferrin receptor (TfR) and V5 from Invitrogen. Phosphatidylinositol-phospholipase C (PI-PLC) and horseradish peroxidase (HRP)-conjugated Cholera toxin B (CTxB) were purchased from Sigma-Aldrich. All fluorescent dyes were purchased from Invitrogen, and all chemical compounds were from Calbiochem (Darmstadt, Germany) or, for recombinant proteins, from R&D Systems. Lysophosphatidic acid (LPA) was purchased from Avanti Polar Lipids (Alabaster, AL). All other reagents were purchased from Sigma-Aldrich unless otherwise indicated.

**Plasmids and Transfection**—The cDNA encoding the open reading frame of human CR-1 was cloned from NTERA2/D1 cells (13). All CR-1-related constructs were generated by PCR-

based methods and cloned into the pCI neo vector (Promega, Madison, WI). The stop codon (TGA) was inserted just after Ser-161 or Ser-169 of the full-length CR-1 (amino acids 1–188, CR1WT) to obtain CR1 $\Delta$ C (Ser-161) or (Ser-169), respectively. The transmembrane portion of ErbB4 (amino acids 651–683) with a FLAG tag was inserted after Ser-169 of CR1WT to obtain CR1TM. The cDNA encoding mouse GPI-phospholipase D (GPI-PLD) was purchased from ATCC (IMAGE clone, 5052822). The open reading frame with Kozak sequence was amplified by PCR using primers: F, ACCATGTCTGCAG-GCAGGGCTGTGG; R, GTCTGAGCTGAAGCTGTAGAC. The PCR product was cloned into pEF6/V5-His TOPO TA expression vector (Invitrogen) in-frame to generate a C-terminal-tagged mGPIPLD-V5 expression vector. DNA sequences were validated by direct sequencing. Transfections were performed using Lipofectamine 2000 (Invitrogen). To establish stable transfecants, transfected cells were selected by G418, at a concentration of 1 mg/ml for 293T and MDCK cells and 2 mg/ml for SW480 cells, respectively.

**Isolation of Detergent-resistant Microdomains**—DRM isolation by nonionic detergent Triton X-100 was performed as previously reported (22). NTERA2/D1 cells were washed with cold phosphate-buffered saline and scraped into 2 ml of MBS (MES-buffered saline; 25 mM MES, pH 6.5, 0.15 M NaCl) containing 1% Triton X-100 and solubilized for 20 min at 4 °C. After homogenization by 10 strokes with a tight-fitting Dounce homogenizer, samples were adjusted to 40% sucrose by addition of 2 ml of 80% sucrose. Then, a 5–40% discontinuous sucrose gradient was formed and centrifuged at 40,000 rpm for 20 h, in an SW40Ti rotor (Beckmann-Coulter, Fullerton, CA). Twelve 1-ml fractions were removed from the top of the tubes and analyzed by Western blotting for CR-1 and for the non-raft-associated membrane protein, TfR using an anti-human TfR antibody (1:2,000) and by dot blotting for the lipid raft marker GM-1 using HRP-conjugated CTxB (1:1,000).

**Phase Separation**—Phase separation by Triton X-114 was performed as previously described (23). Cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% Nonidet P-40, 0.5% deoxycholic acid) with Complete protease inhibitor (Roche Applied Science), and PI-PLC treatment was performed by incubating with 1 unit/ml PI-PLC (Sigma-Aldrich) for 30 min at 37 °C. Cell lysates and conditioned media were then adjusted to 2% Triton X-114 using 2× Triton X-114 solution (40 mM Tris-HCl, pH 8.0, 300 mM NaCl, 4% Triton X-114). After incubation for 1 h on ice, phase separation was carried out by warming up to 37 °C and subsequent centrifugation at 10,000 × g, 25 °C. Before applying for Western blotting, proteins were precipitated with chloroform-methanol precipitation to remove the detergent.

**Western Blot Analysis**—Western blot analysis was performed using 4–20% gradient SDS-PAGE gels (Invitrogen), and CR-1 protein was detected with B3F6 mAb at a 1:5,000 dilution and anti-mouse IgG HRP-conjugated secondary antibody (1:3,000, Amersham Biosciences) (supplemental Fig. S1, A–C). For quantification, 50  $\mu$ g of total cell lysates and 40  $\mu$ l of conditioned media were analyzed for NTERA2/D1 cells, and 20  $\mu$ g of total cell lysates and 20  $\mu$ l of conditioned media were analyzed

for 293T transfectants, respectively. All images of Western blot analysis in this work were visualized, processed, and quantified with an Image Analyzer equipped with LabWorks software (Ultra Violet and Laboratory Products, Upland, CA).

**Enzyme-linked Immunosorbent Assays**—A sandwich-based enzyme-linked immunosorbent assay was performed as previously described (20) with minor modifications. Anti-CR-1 mAb B3F6 (1  $\mu$ g/well) was absorbed to a 96-well Nunc-Immuno Maxisorp Plate (Nunc, Roskilde, Denmark). The plates were blocked with blocking solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD), washed with wash buffer (Kirkegaard & Perry Laboratories), and incubated overnight at 4 °C with 50  $\mu$ l of conditioned media from growth factor-treated cells. Human CR-1 recombinant protein (R&D Systems) was used as a standard (supplemental Fig. S1, D and E). After washing, a rabbit polyclonal anti-CR-1 antibody (1:3,000) was added to the plates for 1 h at room temperature. The plates were then washed five times with washing buffer and incubated with anti-rabbit IgG HRP-conjugated antibody (1:3,000, Amersham Biosciences) for 1 h at room temperature. The plates were developed with 3,3',5,5'-tetramethylbenzidine peroxidase substrate (Kirkegaard & Perry Laboratories), and reactions were quenched with stop solution (Kirkegaard & Perry Laboratories). Absorbance was read at 450 nm.

**Fluorescence Imaging**—Cells were grown for overnight in chambered slides. After washing with phosphate-buffered saline, cells were fixed in 4% paraformaldehyde. Depending on the experiment, cells were permeabilized with 0.2% Triton X-100. After blocking, CR-1 was labeled with 5  $\mu$ g/ml MAB2771 and detected with Alexa Fluor 488-conjugated secondary antibody (Invitrogen). Plasma membrane and lipid rafts were detected with 5  $\mu$ g/ml wheat germ agglutinin-Alexa Fluor 594 conjugate and with 1  $\mu$ g/ml CTxB-Alexa Fluor 594 conjugate (Invitrogen), respectively. Prolong Gold Antifade reagent with DAPI (Invitrogen) was used as a mounting medium. For confocal images, a Zeiss LSM 510 NLO Meta confocal system (Carl Zeiss, Göttingen, Germany) with an Axiovert 200M inverted microscope equipped with a 63 $\times$  numerical aperture 1.4 Plan-Apochromat oil immersion objective lens was used. Z stacks were collected with Zeiss AIM software using a multitrack configuration.

**FACS Analysis**—293T transfectants were collected with phosphate-buffered saline containing 4 mM EDTA. After washing with ice-cold FACS buffer (phosphate-buffered saline with 0.1% bovine serum albumin), 1.0  $\times$  10<sup>5</sup> cells were incubated for 20 min with anti-human CR-1 phycoerythrin-conjugated antibody (FAB2772P) at a dilution of 1:50. Cells were then pelleted, resuspended in 500  $\mu$ l of ice-cold FACS buffer, and analyzed using a FACScan instrument (BD Biosciences).

**Migration Assay**—Transwell migration assay of HUVECs was performed as previously described (21) with some modifications. Briefly, 24 h prior to the assay, the culture medium of 293T or SW480 transfectants, which were seeded in the bottom chamber, were replaced with serum-free medium with or without growth factors or chemicals. 5  $\times$  10<sup>4</sup> serum-starved HUVECs were seeded in the upper chamber of 8- $\mu$ m pore filter 24-well Transwell plates (Corning, Acton, MA).

After 12–16 h, cells were fixed and stained, and cells on the upper side of the filters were wiped away with cotton swabs. Migrated cells on the bottom side of the filter were quantified using IMAGE (National Institutes of Health) software. Each experiment was performed in triplicates and repeated at least twice in independent culture conditions.

**Direct Co-culture Assay**—HUVECs were labeled with Cell-Tracker green 5-chloromethylfluorescein diacetate (Invitrogen) prior to the assay. 5  $\times$  10<sup>4</sup> labeled HUVECs were seeded on confluent cultures of 293T transfectants that had been grown in 6-well plates in serum-free medium. After 12–16 h, cells were fixed and counter staining was performed with rhodamine-conjugated phalloidin (Invitrogen) and DAPI. Images were taken by fluorescence microscopy, on an IX51 inverted microscope equipped with a 20 $\times$  0.4-numerical aperture objective lens (Olympus, Tokyo, Japan). For quantification, HUVECs with sprouting morphology (spindle shapes and/or processes) were counted in total 70–135 CellTracker-positive HUVECs/field under low power magnification. Counting was performed for three different fields in a blinded manner, and three independent experiments were performed.

**siRNA and RT-PCR Analysis**—siRNAs against GPI-PLD were purchased from Ambion (Foster City, CA). Sequences are as below follows: siGPIPLD1 sense, GGAAUCUUAGGACCAUGGtt; antisense, CCAUGGUCCUAAGGAAUCCtt; si-GPIPLD2 sense, GCUAUUGAUUUUCACGGCtt; antisense, AGCCGUGAAAUCAAUAGCTC; siGPIPLD3 sense, GCU-CUGGAGUUUCUUCAGCtt; and antisense, GCUGAA-GAAACUCCAGAGCtc. These sequences contain 1- to 4-nucleotide mismatches with mouse GPI-PLD, which was used for the rescue experiment. Mixture of nonspecific Control siRNAs #1, #2, and #3 (Dharmacon, Chicago, IL) were used for a negative control. Subconfluent 293T or SW480 cells were transfected with a total of 30  $\mu$ M siRNAs using Lipofectamine 2000. Because the knockdown efficiencies of each siRNA were not sufficient (<50% inhibition), we used a mixture of three siRNAs and achieved a maximum inhibition of >70%. RT-PCR was performed using Supermix (Invitrogen) according to manufacturer's instructions at the indicated cycles. A PCR primer set for human GPI-PLD was purchased from Superarray (Frederick, MD).

**Mass Spectrometric Analysis of Released CR-1**—The cultured media from CR-1-transfected Per-C6 cells was harvested and clarified, and the released CR-1 protein was affinity-purified by binding to the B3F6 mAb coupled to CNBr-activated Sepharose.

**Deglycosylation, Reduction, and Alkylation of Shed CR-1—N-Linked glycans were removed from the protein with peptide N-glycosidase F. About 1.5  $\mu$ l of peptide N-glycosidase F (2.5 milliunits/ $\mu$ l, Prozyme, San Leandro, CA) was added to 40  $\mu$ l of a solution containing ~10  $\mu$ g of protein. The solution was incubated at 37 °C overnight. The deglycosylated protein was then reduced with 40 mM dithiothreitol in 6 M guanidine hydrochloride for 2 h at 37 °C, and alkylation was done by adding 0.5  $\mu$ l of 4-vinylpyridine into 50  $\mu$ l of the solution. The solution was incubated at room temperature in the dark for 60 min. The alkylated proteins were recovered by precipitation with 40 volumes of –20 °C ethanol. The solution was stored at –20 °C for**



## Shedding of Cripto-1

1 h and then centrifuged at 14,000 × g for 8 min at 4 °C. The supernatant was discarded, and the precipitate was washed once with -20 °C ethanol.

**Trypsin Digestion**—About 10 µg deglycosylated and alkylated protein was digested with 7% (w/w) of trypsin (Promega) in 1 M urea, 0.2 M Tris-HCl, pH 8.0, 1 mM CaCl<sub>2</sub>, for 5 h at room temperature; the final volume was 50 µl.


**Separation and Analysis of the Digested Shed CR-1 Protein**—The tryptic digest was analyzed on an liquid chromatography-MS/MS system composed of a nano-flow high-performance liquid chromatograph (Dionex, Sunnyvale, CA) and a QSTAR XL mass spectrometer (Applied Biosystems). The high-performance liquid chromatograph was equipped with a 0.3-mm × 1-mm Pepmap C18-trap column for desalting and a 0.075-mm × 150-mm, 100-Å, Pepmap C18 column for separation. Peptides were eluted with a 70-min linear gradient (0–50% acetonitrile) in 0.03% trifluoroacetic acid at a flow rate of 200 nl/min. MS and MS/MS spectra were acquired using information-dependent acquisition and switched automatically between MS and MS/MS. The nanoelectrospray was generated with a nanoelectrospray ionization source (Protana, Toronto, Canada) using a PicoTip needle (15-µm inner diameter, New Objectives, Woburn, MA) maintained at a voltage of 1700 V. MS/MS spectra were collected in the *m/z* range of 50–2,200, and the collision energy setting was automatically determined by the information-dependent acquisition based on the *m/z* values of each precursor ion.

**Statistical Analysis**—Student's *t* test was used to determine the statistical significance of the quantitative results. Results with a *p* value of <0.05 were considered statistically significant.

## RESULTS

**CR-1 Localization in Lipid Rafts**—The GPI-anchorage of CR-1 to the cell membrane has been previously reported by the ability of bacterial PI-PLC to release CR-1 from cultured cells (17). We further demonstrated that CR-1 exhibits pericellular characteristics of a GPI-anchored protein in that CR-1 can be localized to lipid raft domains on the plasma membrane by immunocytochemical analysis in human embryonal carcinoma NTERA2/D1 cells, from which CR-1 was isolated and cloned and is expressed at a relatively high level (1). CR-1 exhibited a punctate staining pattern, a proportion of which was co-localized with the lipid raft marker GM-1, which has been labeled with CTxB (Fig. 1A). To confirm the results from imaging analysis, biochemical isolation of DRMs was performed in NTERA2/D1 cells. Detergent resistance has been considered as a biochemical characteristic of lipid rafts (24). CR-1 protein was found to be enriched in DRMs, which contain GM-1 but do not contain a non-raft membrane protein TfR (25), although a more substantial amount of immunoreactive CR-1 was found to be associated in the soluble fractions (fractions 9–12, Fig. 1B).

Because apical sorting is one of the well known characteristics of GPI-anchored proteins, we examined the CR-1 localization in a well established model of cell polarity, MDCK cells (26). In fully polarized MDCK cells stably transfected with CR-1, CR-1 was stained mainly on the apical surface (supplemental Fig. S2A). A substantial amount of CR-1 protein was detected in the condi-



**FIGURE 1. Lipid raft localization and release of CR-1 protein.** **A**, NTERA2/D1 cells were stained with anti-CR-1 mAb (green), and lipid raft marker GM-1 was labeled with CTxB (red) without permeabilization and analyzed by confocal microscopy (*upper panel*). Magnified images for the marked regions in the *upper panel* are shown in the *lower left panel*. Negative controls without primary antibody are shown in the *lower right panel*. Nuclei were stained with DAPI (blue) in all merged images. Scale bar = 10 µm. **B**, biochemical isolation of DRMs with 1% Triton X-100 by sucrose-gradient centrifugation of NTERA2/D1 cells. The gradient fractions (*lanes 4–12*) were analyzed with Western blot analysis for CR-1. Transferrin receptor (*TfR*) was used as a control for non-raft membrane protein. The lipid raft marker GM-1 in the same samples was detected with HRP-conjugated CTxB by dot-blot analysis. **C**, comparative study of cell-associated (CL) and released (CM) CR-1 with or without serum by semi-quantitative Western blot analysis (see Table 1 and supplemental Fig. S1, *A–C*). A representative blot for NTERA2/D1 cells is shown. The indicated amount of recombinant human CR-1 protein was used as a standard.

**TABLE 1**  
**Semi-quantitative analysis of cell-associated and released CR-1**

	Cell extracts		Conditioned media	
	ng/1 µg total protein	ng/ml		
293T CR1 WT (serum-free)	~1.3	~36		
293T CR1 WT (10% serum)	~1.4	~1.1-fold	>500	>14-fold
NTERA2/D1 (serum-free)	~0.16	~4		
NTERA2/D1 (10% serum)	~0.18	~1.1-fold	~130	~32-fold

293T CR1 WT cells or NTERA2/D1 cells were cultured for 24 h with indicated conditions. The amounts of released and cell-associated CR-1 were quantified by Western blot analysis (see Fig. 1C and supplemental Fig. S1, *A–C*) and compared to standard amounts of recombinant CR-1 after densitometric scanning. Values represent average of four independent experiments.

tioned medium obtained from the apical side but not from the basal side in CR-1-expressing MDCK cells (supplemental Fig. S2B). These results suggest that CR-1 is sorted to the apical side of the plasma membrane in polarized epithelial cells.


**Regulation of CR-1 Shedding by Serum and Growth Factors**—To evaluate the extent of CR-1 secretion into the medium, we compared the amount of released and cell-associated CR-1 by semi-quantitative Western blot analysis using recombinant human CR-1 protein as a standard (Table 1, Fig. 1C, and supplemental Fig. S1, *A–C*). As summarized in Table 1, when cells were cultured in serum-free medium, little CR-1 protein was detected in the conditioned medium

of 293T cells stably transfected with wild-type CR-1 (293T CR1WT cells) and in the conditioned medium from NTERA2/D1 cells that express endogenous CR-1 (~36 ng/ml and ~4 ng/ml, respectively). However, when these cells were cultured in the presence of 10% serum, a higher amount of CR-1 was detected in the conditioned media from 293T and NTERA2/D1 cells (>500 ng/ml and ~130 ng/ml, respectively), which represents >14- and ~32-fold increase in comparison with release of CR-1 under serum-free conditions. These concentrations of CR-1 in the medium are comparable with the concentration of exogenous recombinant CR-1 protein that is required to induce several different cellular responses (100–200 ng/ml) (13).

Because the difference in cell viability after 24-h cultures, in the presence or absence of serum, could affect the amount of released CR-1 protein in the conditioned medium, we evaluated the short term effect of serum on shedding of CR-1. Heat-inactivated serum in which a number of heat-labile lipases and proteinases had been inactivated could induce an increase of >3-fold in shedding of CR-1 in SW480 colon carcinoma cells transfected with wild-type CR-1 expression vector (SW480 CR1 cells) within 30 min (Fig. 2A). SW480 colon carcinoma cells were selected because this cell line expresses low amounts of endogenous CR-1 (1, 3). The effect of heat-inactivated serum was also observed in other cell types, such as 293T CR1WT and in NTERA2/D1 cells that express native CR-1 (data not shown). This effect of serum is dependent on phospholipase C $\gamma$  (PLC $\gamma$ ) and protein kinase C (PKC), because serum-induced CR-1 shedding was inhibited in a dose-dependent manner by the PLC $\gamma$  inhibitor U73122 (Fig. 2B) and by the PKC-specific inhibitor GF109203X, respectively (Fig. 2C). Phorbol 12-myristate 13-acetate (PMA), which is known to activate diacylglycerol-dependent PKCs, was able to mimic the effect of serum on facilitating CR-1 shedding by nearly 3-fold in both 293T CR1WT cells (data not shown) and SW480 CR1 cells (Fig. 2D).

These findings strongly suggest that serum factor(s) can induce CR-1 shedding through activation of PLC $\gamma$  and PKC. To identify endogenous regulatory factors that might enhance CR-1 shedding from cells and that might be present in serum, the levels of released CR-1 were examined after stimulation of 293T CR1WT and SW480 CR1 cells with different growth factors and cytokines using an enzyme-linked immunosorbent assay (Table 2). We found that nine distinct growth factors, including EGF, heparin binding-EGF, hepatocyte growth factor, fibroblast growth factor-2, LPA, interleukin-6 (IL-6), IL-8, tumor necrosis factor  $\alpha$ , and interferon  $\gamma$ , significantly stimulated CR-1 shedding. Some of the factors, including LPA, IL-6, and IL-8 had cell-type-specific effects. For example, LPA strongly induced CR-1 shedding in SW480 CR1 cells but had no significant effect on CR-1 shedding in 293T CR1WT cells.

**Growth Factors Induce Endothelial Cell Migration by Enhancing CR-1 Shedding**—Because EGF and LPA are involved in stimulating tumor progression and tumor angiogenesis (27, 28), and because CR-1 has also been shown to stimulate angiogenesis (16), we hypothesized that these factors might induce



**FIGURE 2. Inducible shedding of CR-1 by serum and PMA.** *A*, rapid induction of CR-1 shedding by serum in SW480 CR1 cells. Cells were stimulated with 5% FBS for 0–60 min. Released CR-1 in the conditioned medium (CM) and cell-associated CR-1 in total cell lysates (CL) were evaluated by Western blot analysis. EV, empty vector; RDU, relative densitometry unit. *B* and *C*, effect of U73122 or GF109203X (GFX) on serum-induced CR-1 shedding. SW480 CR1 cells were treated with or without 5% serum for 30 min with the indicated dose of indicated chemicals, and released CR-1 in the conditioned medium was analyzed by Western blotting. Cells were pretreated with chemicals 30 min before the treatment with serum. Me<sub>2</sub>SO (DMSO) was used for vehicle controls. U73343 was used for a negative control analogue for U73122. *D*, CR-1 release by PMA. SW480 CR1 cells were stimulated with 50 nM PMA for 0–120 min. Released (CM) and cell-associated CR-1 (CL) was analyzed by Western blotting.

endothelial cell migration by facilitating the release of CR-1 from the tumor cell membrane. The effect of LPA and EGF was therefore examined on SW480 colon cancer cells. The induction of CR-1 shedding by LPA or EGF in transfected SW480 CR1 cells that had been grown in serum-free medium was confirmed by Western blot analysis (Fig. 3A). CR-1 shedding induced by LPA or EGF was inhibited by the PKC inhibitor

## Shedding of Cripto-1

**TABLE 2**

### Effect of growth factors on CR-1 shedding

293T CR1WT cells or SW480 CR1WT cells were stimulated for 6–8 h with the indicated factors (EGF, HB-EGF, FGF-2, HGF, IL-6, and TNF $\alpha$ , 50 ng/ml; LPA, 5  $\mu$ M; IL-8, 100 ng/ml; and IFN $\gamma$ , 10 ng/ml). After stimulation, conditioned medium was collected and enzyme-linked immunosorbent assay was performed as described under “Experimental Procedures.” Values represent average (ng/ml)  $\pm$  S.D. of four independent experiments.

	293T CR1WT cells	SW480 CR1WT cells
Control	12.6 $\pm$ 5.7	8.5 $\pm$ 1.8
EGF	55.3 $\pm$ 8.1 <sup>a</sup>	43.3 $\pm$ 6.7 <sup>a</sup>
HB-EGF	59.4 $\pm$ 16.0 <sup>a</sup>	44.7 $\pm$ 5.7 <sup>a</sup>
FGF-2	58.0 $\pm$ 18.4 <sup>a</sup>	27.6 $\pm$ 3.2 <sup>a</sup>
HGF	52.6 $\pm$ 14.6 <sup>a</sup>	25.5 $\pm$ 2.2 <sup>a</sup>
LPA	7.7 $\pm$ 3.5	56.8 $\pm$ 11.6 <sup>a</sup>
IL-6	39.2 $\pm$ 11.3 <sup>a</sup>	12.8 $\pm$ 4.2
IL-8	12.4 $\pm$ 4.1	28.6 $\pm$ 8.0 <sup>a</sup>
TNF $\alpha$	60.4 $\pm$ 19.0 <sup>a</sup>	39.2 $\pm$ 13.2 <sup>a</sup>
IFN $\gamma$	41.0 $\pm$ 12.3 <sup>a</sup>	30.0 $\pm$ 10.0 <sup>a</sup>

<sup>a</sup>*p* < 0.05 compared with control by Student’s *t*-test.

GF109203X (data not shown), suggesting that these factors utilize a pathway similar to that induced by serum and by PMA.

We then evaluated the biological response of CR-1 shedding induced by EGF and LPA in facilitating HUVEC migration. EGF or LPA had weak direct effects on endothelial cell migration unlike vascular endothelial growth factor (Fig. 3B). The effect of CR-1 shedding on HUVEC migration was then evaluated with an indirect co-culture assay (Fig. 3C) using SW480 cells, which express little amount of CR-1 protein (Fig. 2A). Pretreatment of SW480 CR1 cells that were expressing an exogenous CR-1 expression vector with EGF or LPA strongly induced migration of endothelial cells, whereas these factors had significantly weaker effects on SW480 cells transfected with empty vector (SW480 EV cells) (Fig. 3D). These results indicate that EGF or LPA can induce endothelial cell migration toward tumor cells by inducing the release of CR-1 from tumor cells. We also tested the effect of an EGF receptor (EGFR) tyrosine kinase inhibitor, PD168393, on EGF-mediated CR-1 shedding. PD168393 dose-dependently inhibited EGF-mediated CR-1 shedding from SW480 CR1 cells at concentrations of 0.2–1.0  $\mu$ M (Fig. 3E), which corresponds to the dose of PD168393 necessary to inhibit phosphorylation of the EGFR and of signaling molecules that are downstream of EGFR (29). PD168393 significantly suppressed the induction of endothelial cell migration by EGF-treated SW480 CR1 cells at the same range of concentrations (Fig. 3F), suggesting that inhibiting the EGFR may have an indirect effect for suppression of tumor angiogenesis by the ability to block CR-1 shedding from tumor cells.


**Distinct Roles between Soluble and Membrane-bound Forms of CR-1**—To more fully evaluate the detailed mechanism of biological activity of secreted CR-1, three artificial mutants of CR-1 in the C-terminal domain were generated: a soluble CR-1, which lacks the GPI signal (CR1 $\Delta$ C Ser-161 and Ser-169), and a transmembrane CR-1 (CR1TM) in which the GPI signal was replaced by the TM domain of the EGF receptor-related receptor ErbB4, which is not cleavable by phospholipases (Fig. 4A). SDS-PAGE mobility of each product in the cell lysates was compatible with the estimated size from the difference in amino acid sequences (Fig. 4B). High amounts of both CR1 $\Delta$ C mutant proteins were detected in the conditioned medium containing

1% serum, whereas a lower amount of CR1WT, and none of CR1TM, were detected (Fig. 4C). Immunocytochemical analysis in transiently transfected 293T cells confirmed the cell-surface localization of CR1WT and CR1TM without permeabilization following co-staining with a membrane marker wheat germ agglutinin (Fig. 4, D and F). In contrast, CR1 $\Delta$ C Ser-161 (Fig. 4E) and Ser-169 (data not shown) mutants were undetectable without permeabilization. Intracellular trans-Golgi network localization of CR1WT, CR1 $\Delta$ C Ser-161, and CR1TM was detected only after permeabilization with Triton X-100, as assessed by co-localization with a Golgi marker DsRed-Golgi (Fig. 4, G–I). Similar staining patterns with each mutant were obtained in transiently transfected COS7 cells (supplemental Fig. S3, A–F). In COS7 cells, a weak signal of extracellular deposits of CR-1 was detectable around the transfected cells in both CR1 $\Delta$ C Ser-161 (data not shown) and Ser-169 (supplemental Fig. S3B), which was likely due to the higher amount of the overexpressed protein than that found in the CR-1-transfected 293T cells. The cell-surface expression of CR1WT and CR1TM but not soluble forms of CR-1 mutants in stably transfected 293T cells were confirmed by live cell staining with an anti-CR-1 phycoerythrin-conjugated antibody followed by FACS analysis (Fig. 4J).

The ability of each mutant to stimulate HUVEC migration was then assessed in an indirect co-culture migration assay with HUVECs and 293T cells that were stably transfected with empty vector or each CR-1 mutant (293T EV, CR1WT, CR1 $\Delta$ C (Ser-161), (Ser-169), or CR1TM cells) (Fig. 5A). Under the serum-free conditions where little of the GPI-anchored CR-1 protein is released (Table 1), only 293T CR1 $\Delta$ C (Ser-161 and Ser-169) cells could stimulate migration of HUVECs as compared with 293T EV cells (Fig. 5B). The serum-free conditioned medium from only the 293T CR1 $\Delta$ C (Ser-169) cells could induce a 2- to 4-fold increase in phosphorylation of p42/44 MAPK and Akt, but not Smad2 phosphorylation in serum-starved HUVECs (Fig. 5C), suggesting that the effect of a soluble form of CR-1 is dependent on a Nodal-independent, MAPK/PI3K-Akt-dependent pathway as previously demonstrated (16).

To validate the biological activity of the CR-1 mutants in direct cell-to-cell interactions, a direct co-culture assay of fluorescence-labeled HUVECs with 293T transfectants was performed (Fig. 5A). In contrast to the indirect migration assay, when HUVECs were directly seeded onto 293T cells expressing either CR1WT, CR1TM, or CR1 $\Delta$ C (Ser-169), all of the CR-1 transfectants could equally facilitate endothelial cell sprouting (Fig. 5, D and E), suggesting that cell-surface CR-1 is able to induce a response through a direct interaction with endothelial cells.

**GPI-PLD Regulates CR-1 Shedding**—The present results suggested that the release of CR-1 as a soluble factor may be important with respect to the ability of CR-1 to induce endothelial cell migration, leading us to delineate the mechanism(s) by which CR-1 shedding from the cell membrane might occur. We performed Triton X-114 phase partitioning to clarify whether released CR-1 is free from lipid anchoring (Fig. 6A). Cell-associated CR-1 was enriched in the detergent phase and not in the aqueous phase. However, PI-PLC treatment released a majority



**FIGURE 3. Effects of LPA and EGF on shedding of CR-1 and endothelial cell migration.** *A*, confirmation of the effect of LPA and EGF on CR-1 shedding by Western blot analysis. SW480 CR1 cells were stimulated with the indicated factors for 6 h. *B*, direct effect of LPA and EGF on migration of HUVECs. Transwell migration assay of HUVECs was performed for the indicated factors at the indicated concentrations. Vascular endothelial growth factor (50 ng/ml) was used as a positive control. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$  compared with Control. *C*, scheme of indirect co-culture migration assay. *D*, indirect effect of LPA and EGF on migration of HUVECs that are co-cultured with SW480 EV or CR1 cells. SW480 EV or CR1 cells were seeded on the bottom chamber and pretreated with indicated factors (5  $\mu\text{M}$  for LPA and 50 ng/ml for EGF). After 24 h, Transwell migration assay of HUVECs was performed. N.S.,  $p > 0.05$ . *E*, effect of PD168393 on CR-1 shedding. SW480 CR1 cells were pretreated with the indicated concentrations of PD168393 for 30 min and stimulated with EGF (50 ng/ml) for 6 h. Conditioned medium was analyzed by Western blotting. *F*, effect of PD168393 on CR-1 shedding-mediated endothelial cell migration. The co-culture migration assay of HUVECs with SW480 CR1 cells was performed with the indicated concentration of PD168393 in the same condition with *D*. SW480 CR1 cells were pretreated PD168393 30 min prior to stimulation with EGF. N.S.,  $p > 0.05$ . All graphs represent mean  $\pm$  S.D. of triplicate experiments.

of the CR-1 protein into the aqueous phase. The electrophoretic mobility of the GPI-digested form was slightly slower than the undigested form. Most of the released CR-1 in the conditioned medium was partitioned into the aqueous phase and had an electrophoretic mobility similar to PI-PLC-treated CR-1, suggesting that the released form of CR-1 shedding is free from lipid anchoring. Shedding of CR-1 may not be mediated by proteolytic digestion because increasing concentrations of serum stimulated release of CR1WT but failed to stimulate the release of CR1TM, which tethers CR-1 to the cell membrane via a transmembrane domain (Fig. 6B). These results may suggest


that CR-1 shedding is mediated by the digestion of the GPI linkage.


GPI-PLD is involved in facilitating the shedding of a number of GPI-anchored proteins in mammalian cells (30). Serum-induced CR-1 shedding was nearly completely inhibited by the GPI-PLD inhibitor 1, 10-phenanthroline (PNT) (31) (Fig. 6C). In contrast, CR-1 shedding in the absence of serum was induced by 2- to 3-fold by suramin (SRM), which is reported to enhance the action of the membrane-bound GPI-phospholipases (23). RT-PCR analysis revealed that GPI-PLD mRNA is expressed in 293T, SW480, and

## Shedding of Cripto-1

NTERA2/D1 cells (Fig. 6D). To more fully determine whether GPI-PLD is involved in directly regulating CR-1 shedding, selective knockdown experiments using human

GPI-PLD-specific siRNAs (si-hGPIPLD) were undertaken. si-hGPIPLD suppressed GPI-PLD mRNA expression ~70% in 293T CR1WT cells (Fig. 6E), and constitutive CR-1 shed-





**FIGURE 5. Activity of soluble or membrane-bound forms of CR-1 mutants on endothelial cells.** *A*, indirect co-culture migration assay and direct co-culture assay (see “Experimental Procedures”). *B*, indirect co-culture migration assay using 293T cells, which had been stably transfected with the indicated expression vectors. Migration of HUVECs was evaluated. The values represent mean  $\pm$  S.D. of a typical experiment performed in triplicate. \*,  $p < 0.05$  compared with EV. *C*, phosphorylation status of p42/44 MAPK, Akt, and Smad2 in HUVECs. HUVECs were treated with serum-free conditioned medium from 293T transfectants for 15 min. Phospho-/total protein ratio was quantified by densitometric analysis (bottom of each panel). *D* and *E*, direct co-culture assay using 293T cells, which had been stably transfected with indicated expression vectors. HUVECs were seeded on confluent monolayers of 293T transfectants. 5-chloromethylfluorescein diacetate labeled HUVECs (green) were visualized with a fluorescence microscope (*upper panels*). Counter staining was performed with F-actin (red) and DAPI (blue) (*lower panels* for three-color merged images). HUVECs with sprouting morphology (arrowhead) were quantified as described under “Experimental Procedures” (*E*). Scale bar = 50  $\mu$ m. \*,  $p < 0.05$  compared with EV. The values represent mean  $\pm$  S.D. of three independent experiments.

ding in the presence of serum was inhibited  $>50\%$  after the attenuation of GPI-PLD expression (Fig. 6*F*), suggesting that CR-1 shedding is mediated by the enzymatic activity of GPI-PLD.

We then evaluated the effect of GPI-PLD overexpression on CR-1 shedding. Transient transfection of C-terminal V5-tagged mouse GPI-PLD cDNA (mGPIPLD-V5) strongly induced shedding of CR1<sup>WT</sup> into the conditioned medium from 293T cells that had been grown in serum-free medium but had little effect on CR1<sup>TM</sup> (Fig. 6*G*). A substantial amount of mGPIPLD-V5 protein was detected in conditioned medium

(Fig. 6*G*), which is consistent with the previous description that GPI-PLD is a secreted enzyme (32, 33). Similar results were obtained with a wild-type (non-tagged) mouse GPI-PLD construct (data not shown). FACS analysis revealed a decrease of the cell-surface CR1<sup>WT</sup> but not of CR1<sup>TM</sup> by GPI-PLD overexpression (Fig. 6*H*), indicating that GPI-anchored CR-1 had been cleaved from the cell surface by overexpressed GPI-PLD. Overexpression of mouse GPI-PLD was also able to induce CR-1 shedding in stably transfected 293T CR1<sup>WT</sup> cells (Fig. 6*I*) and to rescue the attenuation of CR-1 shedding by siRNAs against human GPI-PLD (Fig. 6*J*).


**FIGURE 4. Generation of CR-1 mutants in the C-terminal domain.** *A*, scheme of CR-1 mutants. *B* and *C*, validation of expression of each CR-1 mutant in cell lysates and conditioned medium. 293T cells were transiently transfected with indicated expression vectors in the presence of 1% serum. Total cell lysates (*B*) and conditioned media (*C*) were collected 24 h after transfection and were analyzed by Western blot analysis.  $\beta$ -Actin and Ponceau S staining were used as loading controls. Results from the same blot detected by regular ECL or more sensitive ECL plus are shown in *C*. EV was used as a negative control. *D*–*I*, subcellular localization of CR-1 mutants. Immunocytochemistry of indicated CR-1 mutants (green) in transiently transfected 293T cells was performed without permeabilization ( $D_1$ – $F_1$ ) or with permeabilization by Triton X-100 ( $G_1$ – $I_1$ ). Plasma membranes were stained with wheat germ agglutinin in  $D_2$ – $F_2$  (red) and DsRed-Golgi was co-transfected with CR-1 construct in  $G_2$ – $I_2$ . Nuclei were counterstained with DAPI (blue), and three-color merged images are shown in  $D_3$ – $I_3$ . Images were visualized with confocal microscopy. Arrowhead, co-localization of CR-1 with Golgi marker. Scale bar = 20  $\mu$ m. *J*, FACS analysis for the cell-surface expression of each CR-1 mutant. 293T cells stably transfected with indicated expression vectors were stained with anti-CR-1 PE-conjugated antibody and analyzed with FACS. EV was used as a negative control.

## Shedding of Cripto-1

Direct physiochemical evidence of the release of CR-1 by GPI-PLD was obtained by MS analysis of secreted CR-1 in CR-1-transfected Per-C6 cells. The major GPI component of CR-1 has a structure, Ser-NH-(CH<sub>2</sub>)<sub>2</sub>-OPO<sub>2</sub>(OH)ManManMan (phosphoethanolamine)GlcN-Hex (Fig. 7A). The detected mass, 3613.6 Da, for this modified peptide matches the predicted mass, 3613.49. The detected masses for all fragment ions in the MS/MS spectrum of this peptide also match the predicted ion

fragments (Fig. 7B). The detected GPI structure of shed CR-1 is consistent with that of a protein, which is released by GPI-PLD but not by PI-PLC, because the phosphate that should be contained after PI-PLC digestion was not observed.


We then studied the role of GPI-PLD in growth factor-induced CR-1 shedding. LPA-, EGF-, and PMA-induced CR-1 shedding is also mediated by GPI-PLD, because the CR-1 shedding by these factors in SW480 CR1 cells was completely



**A**

MDCRKMARFSYSVWIMAISKAFFL<sub>1</sub>, GLVAGLGHQEFAFPRSRGYLAFRDD  
 SIWPQEEPAIRPRSSQRVPPMGIQHSKELNRTCCLNNGTCMLGSFCACPP  
 SFYGRNCEDHVKENCGSVPHDWTLPKKCSLCKCWHGQLRCFPQAFLP  
 GCDGLVMDEHLVAs<sub>16</sub>, RTPELPPSARTTTFMLVGICLSIQSYY

Cleavage site



**B**




FIGURE 7. A, structural analysis of released CR-1 was performed using MS. B, enlarged MS/MS spectrum of tryptic CR-1 peptide containing residues 140–161. The sequences of the peptide, fragmentation pattern, and detected fragment ions are shown at the top of the panel. Cysteine residues in the peptide are pyridylethylcysteine, because the protein was reduced with dithiothreitol and alkylated with 4-vinylpyridine. "b" designates ions that contain the N-terminal region of the peptide plus one or more amino acid residues generated by collision-induced dissociation. Calculated *m/z* values for some critical ions are shown in parentheses.

blocked by PNT and further enhanced by combination with SRM (Fig. 8A). si-hGPIPLD suppressed GPI-PLD mRNA expression ~70% also in SW480 CR1 cells (data not shown),






FIGURE 8. Effect of GPI-PLD knockdown on EGF-induced CR-1 shedding and endothelial cell migration. A, effect of PNT and SRM on LPA-, EGF-, or PMA-induced CR-1 shedding. SW480 CR1 cells were stimulated under indicated conditions of indicated factors for 6 h, and conditioned medium was analyzed by Western blotting. PNT, 1 mM; SRM, 20 μM. B, effect of GPI-PLD knockdown on EGF-induced CR-1 shedding. SW480 CR1 cells were transfected with indicated siRNAs. After 24 h, medium was replaced with serum-free medium and incubated for 16 h. Cells were then stimulated with 50 ng/ml EGF for 6 h. Released CR-1 was analyzed by Western blotting. C, effect of GPI-PLD knockdown on EGF-induced endothelial cell migration. SW480 CR1 cells that were treated with siRNAs as described in B were used for indirect co-culture migration assay with HUVECs with or without 50 ng/ml EGF stimulation. N.S., *p* > 0.05.

and si-hGPIPLD was able to suppress EGF-induced CR-1 shedding (2.1-fold increase in si-control and 1.4-fold increase in si-hGPIPLD, Fig. 8B). Furthermore, suppression of GPI-PLD expression significantly blocked the ability of

FIGURE 6. Regulation of CR-1 shedding by GPI-PLD. A, Triton X-114 phase separation was performed for cell lysates (CL) and conditioned medium (CM) from 293T CR1WT cells and analyzed by Western blotting. The same cell lysate was treated with 1 unit/ml PI-PLC. A, aqueous phase; D, detergent phase. p42/44 MAPK was used for a representative hydrophilic protein. B, effect of serum in shedding of each CR-1 mutant. 293T cells transfected with the indicated CR-1 mutants were incubated with 0–5% serum for 30 min, and released CR-1 in the conditioned medium was analyzed by Western blotting. C, effect of PNT and SRM on CR-1 shedding. Serum-starved 293T CR1WT cells were treated with or without serum for 30 min with the indicated dose of PNT (upper panel). The same cells were treated with the indicated dose of SRM for 30 min in the absence of serum (lower panel). Released CR-1 in the conditioned medium was analyzed by Western blotting. Ethanol (EtOH) was used for vehicle controls. D, GPI-PLD mRNA expression in indicated cell lines. RT-PCR was performed for 35 cycles for GPI-PLD and 25 cycles for GAPDH. The RNA from 293T cells was processed without reverse transcriptase and shown as a negative control (RT-). E, evaluation of siRNA against GPI-PLD by semi-quantitative RT-PCR. 293T cells were transfected with a total 30 nm of the indicated siRNAs, and RNA was collected 48 h after transfection. si-Control, mixture of three different control siRNAs; si-GPIPLD, mixture of three different specific siRNAs against GPI-PLD. RT-PCR was performed for 30 cycles for GPI-PLD and 20 cycles for GAPDH. F, effect of GPI-PLD knockdown on basal release of CR-1. 293T CR1WT cells were transfected with the indicated siRNAs. After 24 h, medium was replaced with 5% serum containing medium and incubated for 24 h. Conditioned medium was collected, and released (CM) and cell-associated CR-1 (CL) were analyzed by Western blotting. G and J, effect of V5-tagged mouse GPI-PLD (mGPIPLD-V5) overexpression on CR-1 shedding. G, 293T cells were transiently transfected with indicated expression vectors. After 24 h of transfection, total cell lysates (CL) and conditioned media (CM) were collected and analyzed by Western blotting. \*, nonspecific bands. H, 293T cells were transiently transfected with the indicated expression vectors. After 24 h of transfection, cell-surface CR-1 was stained with anti-CR-1 PE-conjugated antibody and analyzed by FACS. I, stably transfected 293T CR1WT cells were transfected with indicated expression vectors. EV was used as a negative control and non-transfected control is also shown (−). After 24 h, total cell lysates (CL) and conditioned media (CM) were collected and analyzed by Western blotting. J, 293T CR1WT cells were co-transfected with the indicated siRNAs and expression vectors. After 24 h, medium was replaced with 5% serum containing medium and incubated for 24 h. Total cell lysates (CL) and conditioned medium (CM) were collected and analyzed by Western blotting.

## Shedding of Cripto-1




FIGURE 9. Mechanism of CR-1-mediated tumor angiogenesis.

SW480 CR1 cells to induce endothelial cell migration upon EGF stimulation (Fig. 8C).

## DISCUSSION

We have previously shown that CR-1 exhibits pro-angiogenic activity through a Nodal-independent, c-Src/MAPK/PI3K-Akt-dependent pathway (16). In the present study, we have further delineated the mechanism by which CR-1 can function as an endothelial migration factor. Soluble forms of CR-1 protein were able to induce endothelial migration in contrast to the cell-associated CR-1. On the other hand, membrane-bound forms (a GPI-anchored or a transmembrane form) of CR-1 were able to induce endothelial cell sprouting through a direct cell-to-cell interaction. These findings suggest that soluble CR-1 can act as a paracrine chemoattractant for endothelial cells and that membrane-bound CR-1, which is expressed on the surface of tumor cells, can locally stimulate endothelial cells to potentially form vessels.

Previous reports have shown that the shedding of GPI-anchored proteins can be induced by various factors (34), some of which were also found to facilitate CR-1 shedding in colon cancer cells, such as PMA (35) and EGF (36). The present study demonstrates that LPA or EGF can stimulate tumor cells that are expressing CR-1 to facilitate shedding, which could then possibly enhance endothelial cell migration. The concentration of CR-1 protein from SW480 cells stimulated with growth factors such as EGF or LPA was ~40–60 ng/ml by enzyme-linked immunosorbent assay, and we have previously reported that the range plasma CR-1 level in the clinical cancer patients was 0.86–19.18 ng/ml. Based on these findings, it is speculated that the local concentration of CR-1 protein in clinical tumor tissues could be high enough for its biological activity. The present findings may also explain one additional indirect mechanism by which either LPA or EGF might induce tumor angiogenesis (27, 28). The fact that an EGFR inhibitor blocked the effect of EGF to facilitate CR-1 shedding and subsequently to attract endothelial cells may suggest the possible usage of EGFR inhibitors to block tumor angiogenesis enhanced by CR-1 shedding (Fig. 9).

This is the first study to define a detailed cellular mechanism by which CR-1 can be released as a soluble growth factor. Native or overexpressed CR-1 protein was released from cells into the conditioned medium by stimuli, such as serum, PMA, or several growth factors or cytokines. Release of GPI-anchored

CR-1 was found to be mediated by GPI-PLD, which is the only identified mammalian phospholipase that can cleave the GPI linkage of GPI-anchored proteins (30). Recent reports have shown that the tumor marker carcinoembryonic antigen, which is also a GPI-anchored protein, is released from cells by the enzymatic activity of GPI-PLD in a regulatory mechanism that is similar to the release of CR-1 (37, 38). In addition, CR-1 was found to be present in the plasma of breast and colon cancer patients, suggesting the possible use of plasma CR-1 levels as a tumor marker (20). Therefore, the regulation of CR-1 shedding might also be important for diagnosis of cancer.

CR-1 shedding by GPI-PLD is inducible by certain stimuli such as serum, EGF, or LPA. A PLC $\gamma$ -PKC intracellular signaling pathway is known to be a common signaling pathway that is activated by these factors (39, 40). In fact, the PLC $\gamma$  inhibitor or the PKC inhibitor blocked CR-1 shedding induced by these factors. These data suggest inducible regulation of the enzymatic activity of GPI-PLD via a PLC $\gamma$ -PKC pathway, although there are no reports of such inducible activation of this enzyme. To prove the inducible activation of this enzyme, analysis based on enzyme assay(s) should be performed in the future. Because GPI-PLD is a secreted enzyme as described previously (33) and as we demonstrated here, the translocation of CR-1 protein could be another possible mechanism of inducible shedding of CR-1 by GPI-PLD.

The importance of ectodomain shedding of cell-associated pro-ligands has previously been described (41). In this context, the EGF family of growth factors are initially synthesized as membrane-bound precursors and processed by a disintegrin and metalloproteinase domain (ADAM) proteases to function as mature ligands (42, 43). Inhibition of shedding of EGF-related growth factors may be effective as a therapeutic target of cancer (44). Initially, CR-1 was discovered as an EGF-related peptide and has since been shown to induce signaling through a Nodal-independent signaling pathway that is similar to pathways that are activated by EGF family ligands through the EGFR (1, 3). Even though the one or more precise mechanisms of this Nodal-independent signaling pathway, including its receptor(s) or functional domain(s), remain to be investigated, it is likely that the shedding of CR-1 might have similar importance with that of other EGF family ligands. This study strongly suggests the possibility that the angiogenic and oncogenic effects of CR-1 might be enhanced by its shedding and that shedding of CR-1 could be a potential target for cancer therapy.

**Acknowledgments**—We are grateful to Brenda W. Jones for providing technical support, to Susan Garfield and Stephen Wincovitch for help in confocal imaging, and to the National Institutes of Health Fellows Editorial Board for assistance with editing.

## REFERENCES

1. Salomon, D. S., Bianco, C., Ebert, A. D., Khan, N. I., De Santis, M., Normanno, N., Wechselberger, C., Seno, M., Williams, K., San Nicola, M., Foley, S., Gullick, W. J., and Persico, G. (2000) *Endocr. Relat. Cancer* **7**, 199–226
2. Shen, M. M. (2007) *Development* **134**, 1023–1034
3. Bianco, C., Strizzi, L., Normanno, N., Khan, N., and Salomon, D. S. (2005) *Curr. Top. Dev. Biol.* **67**, 85–133
4. Xing, P. X., Hu, X. F., Pietersz, G. A., Hosick, H. L., and McKenzie, I. F.

## Shedding of Cripto-1

- (2004) *Cancer Res.* **64**, 4018–4023
5. Strizzi, L., Bianco, C., Normanno, N., Seno, M., Wechselberger, C., Wallace-Jones, B., Khan, N. I., Hirota, M., Sun, Y., Sanicola, M., and Salomon, D. S. (2004) *J. Cell. Physiol.* **201**, 266–276
  6. Wechselberger, C., Strizzi, L., Kenney, N., Hirota, M., Sun, Y., Ebert, A., Orozco, O., Bianco, C., Khan, N. I., Wallace-Jones, B., Normanno, N., Adkins, H., Sanicola, M., and Salomon, D. S. (2005) *Oncogene* **24**, 4094–4105
  7. Sun, Y., Strizzi, L., Raafat, A., Hirota, M., Bianco, C., Feigenbaum, L., Kenney, N., Wechselberger, C., Callahan, R., and Salomon, D. S. (2005) *Am. J. Pathol.* **167**, 585–597
  8. Adkins, H. B., Bianco, C., Schiffer, S. G., Rayhorn, P., Zafari, M., Cheung, A. E., Orozco, O., Olson, D., De Luca, A., Chen, L. L., Miatkowski, K., Benjamin, C., Normanno, N., Williams, K. P., Jarpe, M., LePage, D., Salomon, D., and Sanicola, M. (2003) *J. Clin. Invest.* **112**, 575–587
  9. De Luca, A., Arra, C., D'Antonio, A., Casamassimi, A., Losito, S., Ferraro, P., Ciardiello, F., Salomon, D. S., and Normanno, N. (2000) *Oncogene* **19**, 5863–5871
  10. Yeo, C., and Whitman, M. (2001) *Mol. Cell* **7**, 949–957
  11. Cheng, S. K., Olale, F., Bennett, J. T., Brivanlou, A. H., and Schier, A. F. (2003) *Genes Dev.* **17**, 31–36
  12. Chen, C., Ware, S. M., Sato, A., Houston-Hawkins, D. E., Habas, R., Matzuk, M. M., Shen, M. M., and Brown, C. W. (2006) *Development* **133**, 319–329
  13. Bianco, C., Adkins, H. B., Wechselberger, C., Seno, M., Normanno, N., De Luca, A., Sun, Y., Khan, N., Kenney, N., Ebert, A., Williams, K. P., Sanicola, M., and Salomon, D. S. (2002) *Mol. Cell. Biol.* **22**, 2586–2597
  14. Gray, P. C., Shani, G., Aung, K., Kelber, J., and Vale, W. (2006) *Mol. Cell. Biol.* **26**, 9268–9278
  15. Ding, J., Yang, L., Yan, Y. T., Chen, A., Desai, N., Wynshaw-Boris, A., and Shen, M. M. (1998) *Nature* **395**, 702–707
  16. Bianco, C., Strizzi, L., Ebert, A., Chang, C., Rehman, A., Normanno, N., Guedez, L., Salloum, R., Ginsburg, E., Sun, Y., Khan, N., Hirota, M., Wallace-Jones, B., Wechselberger, C., Vonderhaar, B. K., Tosato, G., Stetler-Stevenson, W. G., Sanicola, M., and Salomon, D. S. (2005) *J. Natl. Cancer Inst.* **97**, 132–141
  17. Minchietti, G., Parisi, S., Liguori, G., Signore, M., Lania, G., Adamson, E. D., Lago, C. T., and Persico, M. G. (2000) *Mech. Dev.* **90**, 133–142
  18. Minchietti, G., Manco, G., Parisi, S., Lago, C. T., Rosa, F., and Persico, M. G. (2001) *Development* **128**, 4501–4510
  19. Yan, Y. T., Liu, J. J., Luo, Y. E. C., Haltiwanger, R. S., Abate-Shen, C., and Shen, M. M. (2002) *Mol. Cell. Biol.* **22**, 4439–4449
  20. Bianco, C., Strizzi, L., Mancino, M., Rehman, A., Hamada, S., Watanabe, K., De Luca, A., Jones, B., Balogh, G., Russo, J., Mailo, D., Palaia, R., D'Aiuto, G., Botti, G., Perrone, F., Salomon, D. S., and Normanno, N. (2006) *Clin. Cancer Res.* **12**, 5158–5164
  21. Watanabe, K., Hasegawa, Y., Yamashita, H., Shimizu, K., Ding, Y., Abe, M., Ohta, H., Imagawa, K., Hojo, K., Maki, H., Sonoda, H., and Sato, Y. (2004) *J. Clin. Invest.* **114**, 898–907
  22. McCabe, J. B., and Berthiaume, L. G. (2001) *Mol. Biol. Cell* **12**, 3601–3617
  23. Lee, J. Y., Kim, M. R., and Sok, D. E. (1998) *Neurochem. Res.* **23**, 899–905
  24. Jacobson, K., Mouritsen, O. G., and Anderson, R. G. (2007) *Nat. Cell Biol.* **9**, 7–14
  25. Muller, H. K., Wiborg, O., and Haase, J. (2006) *J. Biol. Chem.* **281**, 28901–28909
  26. Paladino, S., Pocard, T., Catino, M. A., and Zurzolo, C. (2006) *J. Cell Biol.* **172**, 1023–1034
  27. van Cruijsen, H., Giaccone, G., and Hoekman, K. (2005) *Int. J. Cancer* **117**, 883–888
  28. Sengupta, S., Wang, Z., Tipps, R., and Xu, Y. (2004) *Semin. Cell Dev. Biol.* **15**, 503–512
  29. Bose, R., Molina, H., Patterson, A. S., Bitok, J. K., Periaswamy, B., Bader, J. S., Pandey, A., and Cole, P. A. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103**, 9773–9778
  30. Lauc, G., and Heffer-Lauc, M. (2006) *Biochim. Biophys. Acta* **1760**, 584–602
  31. Metz, C. N., Brunner, G., Choi-Muira, N. H., Nguyen, H., Gabrilove, J., Caras, I. W., Altszuler, N., Rifkin, D. B., Wilson, E. L., and Davitz, M. A. (1994) *EMBO J.* **13**, 1741–1751
  32. Ikezawa, H. (2002) *Biol. Pharm. Bull.* **25**, 409–417
  33. Kung, M., Butikofer, P., Brodbeck, U., and Stadelmann, B. (1997) *Biochim. Biophys. Acta* **1357**, 329–338
  34. Sharom, F. J., and Lehto, M. T. (2002) *Biochem. Cell Biol.* **80**, 535–549
  35. Parkin, E. T., Watt, N. T., Turner, A. J., and Hooper, N. M. (2004) *J. Biol. Chem.* **279**, 11170–11178
  36. Roberts, J. M., Kenton, P., and Johnson, P. M. (1990) *FEBS Lett.* **267**, 213–216
  37. Yamamoto, Y., Hirakawa, E., Mori, S., Hamada, Y., Kawaguchi, N., and Matsuura, N. (2005) *Biochem. Biophys. Res. Commun.* **333**, 223–229
  38. Naghibalhossaini, F., and Ebadi, P. (2006) *Cancer Lett.* **234**, 158–167
  39. Carpenter, G., and Ji, Q. (1999) *Exp. Cell Res.* **253**, 15–24
  40. Newton, A. C. (2001) *Chem. Rev.* **101**, 2353–2364
  41. Arribas, J., and Borroto, A. (2002) *Chem. Rev.* **102**, 4627–4638
  42. Normanno, N., Bianco, C., De Luca, A., and Salomon, D. S. (2001) *Front. Biosci.* **6**, D685–D707
  43. Zhou, B. B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., Yang, G., Li, Y., Yao, W., Vaddi, K., Gazdar, A. F., Friedman, S. M., Jablons, D. M., Newton, R. C., Friedman, J. S., Minna, J. D., and Scherle, P. A. (2006) *Cancer Cell* **10**, 39–50
  44. Singh, A. B., and Harris, R. C. (2005) *Cell. Signal.* **17**, 1183–1193

>\_ SEQ ID NO.1321 474 aa vs.  
 >\_ Cripto-1 188 aa  
 scoring matrix: , gap penalties: -12/-2  
14.5% identity; Global alignment score: -355

10	20	30	40	50	60
MAPPVRLERPFPSPRRFPGLLLAALVLLLSSFSDQCNVPEWLPFARPTNLTDDEFFPIGTY					
: .	..	... :: .	.. .	.. :: . .	
M-----DCRK-----MARFSYSVI---WI----MAISKVFELGLVAG					
10			20	30	
70	80	90	100	110	
LNYE--CRPGYSGRPFPSIICLKNSVWTSAKDKCK-RKSCRNPPDPVNGMAHVIKDIQFGS					
: ... . . .	: .. . . .	. . . . .	: . . . .	: . . .	
LGHQEFAFPSRGYLAFR---DDSIWPQEEPAIRPRSSQRVPP-----MGIQHSK					
40	50	60		70	
120	130	140	150	160	170
QIKYSCPCKGYRLIGSSSATCIISGNTVIWDNKTPVCVDRIICGLPPTIANGDFTSISREYF					
. . . : . . .					
ELNRTC-----CLNGT-----					
80					
180	190	200	210	220	230
HYGSVVVTYHCNLGSRGKKVFELVGEPSIYCTSKDDQVGIWSGPAPQCIIPNKCTPPNVEN					
: . . .			. . .		
CMLGS-----FCA-----					
90					
240	250	260	270	280	290
GILVSDNRSLFSLNEVVEFRCQPGFGMKGPSHVKCQALNKWEPELPCSRVCQPPPDVLH					
: . . .			. . . .		
CPPSFY-----GRNCE-----H					
100					
300	310	320	330	340	350
AERTQRDKDNFSPGQEVFYSCEPGYDLRGSTYLHCTPQGDWSAPAARCEVKSCDDFLGQL					
: . . .		: . . .	. . . .	. . . .	. . . .
DVR---KEN-----C-----GSV-----PHDTWLKP--KCSLCKC--WHGQL					
110			120	130	
360	370	380	390	400	410
PNGHVLFPPLNQLGAKVDFVCDEGFQLKGSSASACVLAGMESLNSSVPVCERKSCETPP					
: . . .		: . . .	: . . .	: . . .	: . . .
RC---FPQAFLPG----CD-GLVMD-----EHLVASRTP-----ELPP					
140	150		160		
420	430	440	450	460	470
VPVNGMVHVITDIHVGSRINYSCTTGHRIGHSSAACILSGNTAHWSMKPPICQREL					
. . .	. . .	. .	. .	. .	. .
SAR----TTTFMLVGI---CL-----SI----QSYY					
170	180				

## Attachment B

>US20060194265\_1321 Sequence 1321 from Patent US 20060194265  
MAPPVRLERPFPSPRRFPGLLLAALVLLSSFSDQCNCVPEWLPFARPTNLTDDEFPIGTYINYECPGYSGRPFPSII  
CLKNSVWTSAKDKCKRKSCRNPPDPVNGMAHVIKDIQFGSQIKYSCPCKYRLIGSSSATCIISGNTVIWDNKTPVCD  
RIICGLPPTIANGDFTSISREYFHYGSVVTYHCNLGSRGKKVFELVGEPSIYCTSKDDQVGIWSGPAPQCIIFPNKCT  
PPNVENGILVSDNRSLFSLNEVVEFRCQPGFMKGPSHVKCQALNKWEPELPSCSRVCQPPDVLAERTQRDKDNF  
SPGQEVFYSCERGYDLRGSTYLHCTPQGDWSPAAPRCEVKSCDDFLGQLPNGHVLFPLNLQLGAKVDFVCDEGFQLK  
GSSASACVIALGMESLNSSVPVCERKSCETPPPVNGMVHVITDIHGSRINYSCTTGHLIGHSSAECILSGNTAH  
WSMKPPICQREL

>sp|P13385|TDGF1\_HUMAN/CRYPTO1  
MDCRKMARFSYSVIWIMAIISKVFELGLVAGLGHQEFAFPRSGYLAFRDDSIWPQEEPAIR  
PRSSQRVPPMGIQHSKELNRTCLNGGTMLGSFCACPPSFYGRNCEHDVRKENCGSVPH  
DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTFMLVGI  
CLSIQSYY

> SEQ ID NO.1321 474 aa vs.  
 > Cripto-1 188 aa  
 scoring matrix: , gap penalties: -12/-2  
14.5% identity; Global alignment score: -355

10	20	30	40	50	60
MAPPVRLERPFPSPRRFPGLLLAALVLLLSSFSDQCNVPEWLPFARPTNLDDFEFFIGTY					
:	..	.. : ..	..	.. :	.. : ..
M-----DCRK-----MARFSYSVI--WI----MAISKVFELGLVAG					
	10		20		30
70	80	90	100	110	
LNYE--CRPGYSGRPFSIICLKNSVWTSAKDKCK-RKSCRNPPDPVNGMAHVIKDIQFGS					
:... : .. : .. : .. : .. : ..					
LGHQEFAFPSRGYLAFR---DDSIWPQEEPAIRPRRSSQRVPP-----MGIQHSK					
	40	50	60		70
120	130	140	150	160	170
QIKYSCPKGYRLIGSSSATCIISGNTVIWDNKTPVCDRIICGLPPTIANGDFTSISREYF					
... : .. : ..					
ELNRTC-----CLNGGT-----					
	80				
180	190	200	210	220	230
HYGSVVVTYHCNLGSRGKKVVELVGEPSIYCTS KDDQVGIWSGPAPQCIIIPNKCTPPNVEN					
: .. : ..					
-----CMLGS-----FCA-----					
	90				
240	250	260	270	280	290
GILVSDNRSLFSLNEVVEFRCQPGFGMKGPSHVKCQALNKWEPELPSCSRVCQPPPDVLH					
: .. : .. : ..					
-----CPPSFY-----GRNCE-----H					
	100				
300	310	320	330	340	350
AERTQRDKDNFSPGQEVFYSCEPGYDLRGSTYLHCTPQGDWSPAAPRCEVKSCDDFLGQL					
: .. : .. : .. : .. : .. : ..					
DVR---KEN-----C-----GSV-----PHDTWLKP--KCSLCKC--WHGQL					
	110		120		130
360	370	380	390	400	410
PNGHVLFPLNLQLGAKVDFVCDEGFQLKGSSASYCVLAGMESLWNSSVPVCERKSCETPP					
: .. : .. : .. : .. : ..					
RC---FPQAFLPG-----CD-GLVMD-----EHLVASRTP-----ELPP					
	140	150		160	
420	430	440	450	460	470
VPVNGMVHVITDIHVGSRINYSCTTGHLIGHSSAECILSGNTAHWSMKPPICQREL					
: .. : .. : .. : ..					
-----SAR-----TTTFMLVGI-----CL-----SI-----QSYY					
	170	180			

## **Attachment C**

>US20060194265\_1321 Sequence 1321 from Patent US 20060194265  
MAPPVRLERPPSRRFPGLLLAALVLLSSFSDQCNCVPEWLPFARPTNLTDDEFFPIGTYLNYECRPGYSGRPFSSII  
CLKNSVWTSAKDKCKRKSCRNPPDPVNGMAHVIKDIQFGSQIKYSCPCKGYRLIGSSSATCIISGNTVIWDNKTPVCD  
RIICGLPPTIANGDFTSISREYFHYGSVVTYHCNLGSRGKKVFELVGEPSIYCTSCKDDQVGIWSGPAPQCIIPNKCT  
PPNVENGILVSDNRSLFSLNEVVEFRCQPGFMKGPSHVKCQALNKWEPELPSCSRVCQPPPDVLHAERTQRDKDNF  
SPGQEVFYSCEPGYDLRGSTYLHCTPQGDWSPAAPRCEVKSCDDFLGQLPNGHVLFPLNLQLGAKVDFVCDEGFQLK  
GSSASACVLAGMESLNSSVPVCERKSCETPPPVNGMVHVITDIHGSRINYSCTTGHLIGHSSAECILSGNTAH  
WSMKPPICQREL

>sp|P13385|TDGF1\_HUMAN/CRYPTO1  
MDCRKMARFSYSVIWIMAISKVFEGLVAGLGHQEFAFPSRGYLAFRDDSIWPQEEPAIR  
PRSSQRVPPMGIQHSKELNRTCCLNGGTMLGSFCACPPSFYGRNCEHDVRKENCGSVPH  
DTWLPKKCSLCKCWHGQLRCFPQAFLPGCDGLVMDEHLVASRTPELPPSARTTFMLVGI  
CLSIQSYY

>\_ SEQ ID NO. 1320 1538 nt vs.  
 >\_ cripto-1 2033 nt  
 scoring matrix: , gap penalties: -12/-2  
 43.5% identity; Global alignment score: -519

10	20	30	40	50	
GTGAGTTTG---GGGATTGTTGTCCACTAACCGGACTCAGAAGGGACTTCCCTGCTCG					
: : :: :					
G-GAGAATCCCCGGAAAGGCTGAGTCTCCAGCTCAAGGTCAAAACG---TCCAAGGCCG					
10	20	30	40	50	
60	70	80	90	100	110
GCTGGCTTCGGTTCTGCTCACCTCCGGATAAATCACGGGTCTCCCGCGCCGCTCA					
: :					
AAAGCCCTCCAGTTCCC--CTGGACGCC---TTGCTC-CTGCTTCTGCTACGACCTTCT					
60	70	80	90	100	
120	130	140	150	160	
TGG----CGC---CTCCCGTCCGTCTCGAGCGTCCCTTCCT-TCCCGGCCT-----					
: :					
GGGGAAAACGAATTCTCATTTCTTAAATTGCCATTTCGCTTAGGAGATGAATG					
110	120	130	140	150	160
170	180		190	200	210
--TTCCTGGGTTGCTTCTGGC---GGCCCTG-----GTGTTGCTGCTGTCCTCCTTCT					
: :					
TTTCCTTGGCTGTTTGGCAATGACTCTGAATTAAAGCGATGCTAACG-CCTCTTTCT					
170	180	190	200	210	220
220	230		240		
CC-----GATCAATGCAATG---TCCCGGAA--TGGC---TTCC-----AT					
: :					
CCCCTAATTGTTAAAAGCTATGGACTGCAGGAAGATGCCCGCTCTCTAACAGTGTGAT					
230	240	250	260	270	280
250	260				
TTG---CCAGGCC--TACCAACCT----AACTG-----A					
: : : : : : : : : : : : : : : :					
TTGGATCATGGCCATTCTAAAGTCTTGAAGTGGGATTAGTTGCCGGCTGGCCATCA					
290	300	310	320	330	340
270	280	290	300	310	
TGACTTTGAGTTCCCATTGGGACATATCTGAAC-----ATGAATGCCG-----CCCT					
: :					
GGAATTGCTCGTCCATCTGGGATACCTGGCCTTCAGAGATGACAGCATTGGCCCCA					
350	360	370	380	390	400
320	330		340	350	360
GGTTATTCCGGAA---GACC---GTTTTCT-ATCATCTGCCT-----AAAAAAACT					
: :					
GGAGGAGCCTGCAATTGGCCTCGGTCTTCCAGCGTGTGCCGCCATGGGATACAGCA					
410	420	430	440	450	460
370		380		390	
400		410			

CAGTCTGGAC-----AAGTGCTAAGGACAAGTGC<sub>A</sub>ACGTAAATCATGTCGTAAT-  
 :  
 CAGTAAGGAGCTAACAGAACCTGCTGCC<sub>T</sub>GAATGGGGAACCTGCATGCTGGGT<sub>C</sub>TT  
 470 480 490 500 510 520  
 420 430 440 450  
 -----CCTCCAGA-T<sub>C</sub>CTGTGAATGGCA-TG---GCAC-ATGTGATCAAAGACAT  
 :  
 TTGTGCCTGCC<sub>T</sub>CCCTCC<sub>T</sub>CTACGGACGGA<sub>T</sub>GTGAGCACGATGTGC<sub>G</sub>CAAAGAGAA  
 530 540 550 560 570 580  
 460 470 480 490 500  
 CCA--GTTCGGATCCC<sub>A</sub>ATTAAATATTCTTG<sub>C</sub>CTA-AAGGATA<sub>C</sub>AC-GACTCATTGGT  
 :  
 CTGTGGGTCTGTGCC<sub>CC</sub>-TGACACCTGGCTGCC<sub>A</sub>AGAAGTGTCC<sub>C</sub>TGTAAATGCT  
 590 600 610 620 630 640  
 510 520 530 540 550  
 TCCTCG-TCTGCCACATGCATCATCTCAGGCA----ACAC---TGTCAT---TTGGGA  
 :  
 GGCACGGTCAGCTCCGCTGCTTC<sub>C</sub>TCAGGCATTCTACCCGGCTGTGATGCC<sub>T</sub>TGTGA  
 650 660 670 680 690 700  
 560 570 580 590 600 610  
 TAATAAAACACCTGTTG-TGACAGAAATTATTGTGGCTACCCCCCACCATGCCAATG  
 :  
 TGGATGAGCACCTCGTGGCTTCAGGACTC---CAGAACTACCACCGTCTGCACGTACTA  
 710 720 730 740 750 760  
 620 630 640 650 660  
 GAGATTCA--CTAG---CATCAGCAG---AGAGTATTTCACTATGGATCAGTGGTG  
 :  
 CCACTTTATGCTAGTTGGCATCTGCCTTCTATACAAAGCT-<sub>A</sub>CTATTAAATCGACATTG  
 770 780 790 800 810 820  
 670 680 690 700 710  
 ACCTA---CCAC---TGCAATCTGG<sub>A</sub>-AGCAGAGGGAAAAGGT<sub>T</sub>TGAGC--TTGTG  
 :  
 ACTTATTTCAGAAATACAATT<sub>T</sub>TAGATATCA---TGCAAAT--TTCATGACCAGTAAAG  
 830 840 850 860 870  
 720 730 740 750 760  
 GGTGAGCCCTCCATATACTGCACCAGCAAAGATGATCA----AGTGGGCAT-----  
 :  
 GCTGCTGCTACAATGT<sub>C</sub>CT--AACTG-AAAGATGATCATTG<sub>T</sub>AGTTGC<sub>C</sub>TTAAAATAAT  
 880 890 900 910 920 930  
 770 780 790 800  
 -----CTGGAGTGGCC----CAGCCC<sub>T</sub>CAGTCATTATA<sub>C</sub>CTAACAAAT---  
 :  
 GAATACAATTCCAAAATGGTCTCTAACATT<sub>C</sub>TTACAGAA<sub>T</sub>ACTACTTCTTACTTCTT<sub>G</sub>  
 940 950 960 970 980 990  
 810 820 830  
 ----GCACGCCTCCAAA-----TGTGGAAAATGGAA-----TAT----TG  
 :  
 CCCTGCC<sub>T</sub>CTCCAAAAAACTACTTCTTTCAAAAGAAAGTCAGCC<sub>A</sub>TATCTCCATT

1000	1010	1020	1030	1040	1050
840	850	860	870	880	890
GTATCTGACAACAGAACGCT-TATTTCCCTAAATGAAGTGTGGAGTTAGGT--GTCAG					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
GTGCCTAAGTCCAGTGTCTTTTTTTTTGAGACGGAGTCTCACTCTGTCAC					
1060	1070	1080	1090	1100	1110
900	910	920	930	940	950
CCTGGCTTGGCATGAAAGGGCCCTCCATG-TGAAGTGCCAGGCCCTGAACAAATGGG-					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
CCAGGC--TGGACTGCAATGACCGATCTGGTCACTGCAA--CCTCCGCATCCGGGG					
1120	1130	1140	1150	1160	1170
960	970	980	990		
----AGCCAGAGT--TACC-AAGCTGCTCCAG----GGTATGTCAGCCACCT--CCAGA					
::::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
TTCAAGCCATTCTCCTGCCTAACGCCTCCAAGTAACTGGGATTACAGGCATGTGTCACCA					
1180	1190	1200	1210	1220	1230
1000	1010	1020	1030	1040	1050
TGTCTGC-ATGCTGAGCGTACCCAAAGGGACAAGGACAACCTTCACCC---GGCAG					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
TGCCCCAGCTAATTTTTTGTATTAGTAGAGATGGG---GGTTTCACCATATTGGCCAG					
1240	1250	1260	1270	1280	
1060	1070	1080	1090		
-----GAAGT-----GTTCTACAGCTGTGAGCCCGGCTACGACCTCAGAGGAT					
:: : :: : :: : :: :: :: :: :: :: :: :: :: :: :: :: ::					
TCTGGTCTCGAACTCTGACCTTGTGATCCATCGATCAGCCTCTCGA-GTGCTGAGATTAC					
1290	1300	1310	1320	1330	1340
1100	1110	1120	1130	1140	
CTACGT-ATTTCGACTGCACACCCCAGGGAGACTGGAGCCCTGCAGCCC--CCAG----					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
ACACGTGAGCAACTGTGCAAGGCCTGGTGTCTTGATACATGTAATTCTACCAAGGTCT					
1350	1360	1370	1380	1390	1400
1150	1160	1170	1180	1190	
----ATGTG-----AAGTGA--AATCCTGTGATGAC-TTCCTGG-GCCAACCTCCT					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
TCTTAATATGTTCTTTAAATGATTGAATTATGTTGAGATTATTGGAGACTAATTC-T					
1410	1420	1430	1440	1450	1460
1200			1210	1220	
AATG--GCCATGTG---CTATTTC-----CACTTAA-----TCTC					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
AATGTGGACCTTAGAATACAGTTGAGTAGAGTTGATCAAAATCAATTAAAATAGTCTC					
1470	1480	1490	1500	1510	1520
		1230			
-----CAGCTT-----GGAGCAA-----AAGTG					
:: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::					
TTTAAAGGAAAGAAAACATCTTAAGGGAGGAACCAGAGTGCTGAAGGAATGGAAGTC					
1530	1540	1550	1560	1570	1580
1240	1250		1260	1270	1280

GATTTT-GTTTGTG-----ATGAAGGATT--CAATTAAAAGGCAGCTCTG  
:: : :: ::  
CATCTGCGTGTGTCAGGGAGACTGGGTAGGAAAGAGGAAGCAAATAGAAGAGAGAGGTT  
1590 1600 1610 1620 1630 1640  
  
1290 1300 1310  
CTA-----GTTACT-----GTGTTTGGC--TGGAAATGGAA-----AG  
:  
GAAAAACAAAATGGGTTACTTGATTGGTAGGTGGTAGAGAAGCAAGTAAAAG  
1650 1660 1670 1680 1690 1700  
  
1320 1330 1340 1350 1360  
CCTT--TCCAATAGCAGTGTCCAGTGTGT---GAACG-TAAATCATGTGA-AACTCCTC  
:  
GCTAAATGGAAGGGCAAGTTCCATCATCTATAGAAAAGCTATATAAGACAAGAACCCCC  
1710 1720 1730 1740 1750 1760  
  
1370 1380 1390 1400  
CAGTT---CCAGTG-----AATGGCATGGTGATG-TGATCACAGACAT-----  
:  
TTTTTTTCCCAGGCATTATAAAAAGAATGAAGCCTCCTAGAAAAAAAATTATACCTC  
1770 1780 1790 1800 1810 1820  
  
1410 1420 1430  
----CCA-----TGTGGATCCAG--AATCAACTATTCT-  
:  
AATGTCCCCAACAGATTGCTTAATAAATTGTGTTCCCTCAAGCTATTCAATTCTTTA  
1830 1840 1850 1860 1870 1880  
  
1440 1450 1460 1470  
--TGTACTACAGGGCACCG-----ACTCATTGGTCACTCATCTGCTGAATGTA  
:  
ACTGTTGTTAGAACAGAAAATGTTCACAAATATATTAGTTGTAACCAAGTGATCAAACTA  
1890 1900 1910 1920 1930 1940  
  
1480 1490 1500 1510  
--TCCTCTCGGGC-----AATAC--TGCCCATGGAGCATGAA-----G  
:  
CATATTGTAAGCCCATTAAACATTGTATATGTGTATGCACAGTAAAATGG  
1950 1960 1970 1980 1990 2000  
  
1520 1530  
CCACCAATTGTC---AACGTGAGTTG  
: : : : : : : :  
AAACTATATTGACCTAAAAAAAAAAAA  
2010 2020 2030

>US20060194265\_1320 Sequence 1320 from Patent US 20060194265 inClaims Organism: Homo sapiens  
GTGAGTTGGGGATTGTGTCCACTAACCGGACTCAGAAGGGACTTCCCTGCTCGCTGGCTTCGGTTCTGCTGC  
ACCTCCGGATAAAATCACGGGTCTCCCGCGCCGCTCATGGCCGCTCCCGTCTCGAGCGTCCCTTCCCTCCGGCG  
CTTTCCCTGGGTGCTTCTGGCGGCCCTGGTGTCTGCTGCTGCTCTCTCGATCAATGCAATGCCCCGAATGGCTTC  
CATTTGCCAGGCCTACCAACCTAACGTGACTTTGACTTTCCCATTGGACATATCTGAACATATGAATGCCGCCCTGGT  
TATTCCCGAAGACCCTTCTATCATCTGCCCTAAAAACTCAGTCTGGACAAGTGCTAAGGACAAGTGCACAAAGCTAAATC  
ATGTCGTAATCCTCCAGATCTGTGAATGGCATGGCACATGTGATCAAAGACATCCAGTTCGGATCCCAAATTAAATATT  
CTTGTCTCTAAAGGATACCGACTCATGGTTCTCTGGCTGCCACATGCATCATCTCAGGCAACACTGTCATTGGATAAT  
AAAACACCTGGTGTGACAGAAATTGGTGGCTACCCACATGCCATGGAGATTCACTAGCATCAGCAGAGA  
GTATTTCACTATGGATCAGTGGTGAACCTACACTGCAATCTTGAAGCAGAGGAAAAGGTGTTGAGCTTGTGGTG  
AGCCCTCCATATACTGCACAGCAAAGATGATCAAGTGGCATCTGGAGTGGCCAGCCCTCAGTGCATTACCTAAC  
AAATGCCACGCCCTCCAAATGGAAATTGGTATCTGACAACAGAAGCTTATTCTTAATGAAGTTGTGGA  
GTTTAGGTGTCAGCCTGGCTTGGCATGAAAGGGCCCTCCCATGTGAAGTGCCAGGCCCTGAACAAATGGGAGCCAGAGT  
TACCAAGCTGCTCCAGGGTATGTCAGCCACCTCCAGATGTCTGCTGAGCGTACCCAAAGGGACAAGGACAACCTT  
TCACCCGGGAGGAAGTGTCTACAGCTGTGAGCCCCGGCTACGACCTCAGAGGATCTACGTATTGCACTGCACACCCCC  
GGGAGACTGGAGCCCTGCAGCCCCCAGATGTGAAGTGAATCTGTGATGACTTCTGGCCAACCTCTTAATGGCCATG  
TGCTATTTCACCTTAATCTCAGCTTGGAGCAAAGTGGATTGTTGATGAAGGATTCTAATTAAAGGCAGCTCT  
GCTAGTTACTGTGTTTGGCTGGAATGGAAAGCCTTGGAAATAGCAGTGTGATGACAGACATCATGTTGGATCCAGAATCA  
ACTATTCTGTACTA  
CAGGGCACCGACTCATTGGTCACTCATCTGCTGAATGTATCCTCTGGGAATACTGCCATTGGAGCATGAAGCCACCA  
ATTGTCAACGTGAGTTG

Cripto-1

ggagaatccc	cggaaaggct	gagtctccag	ctcaaggc	taaaacgtccaa	ggccgaaagc	60
cctccagttt	ccccctggacg	ccttgctct	gcttcgtcta	cgacccttctg	gggaaaacga	120
atttctcatt	ttcttcattaa	attgcattt	tcgcctttagg	agatgaatgt	tttcctttgg	180
ctgttttggc	aatgactctg	aattaaagcg	atgctaaccg	ctctttcccc	cctaatttgtt	240
aaaagctatg	gactgcagga	agatggcccg	cttctttac	agtgtgattt	ggatcatggc	300
catttctaaa	gtcttgaac	tgggattagt	tgccgggctg	ggccatcagg	aatttgcctcg	360
tccatctcgg	ggataacctgg	ccttcagaga	tgacagcatt	tggcccccagg	aggagcctgc	420
aatttgcgct	cggtcttccc	agegtgtgcc	gcccatgggg	atacagcaca	gtaaggagct	480
aaacagaacc	tgctgcctga	atgggggaac	ctgcatgcg	gggtcctttt	gtgcctgccc	540
tccctccctt	tacggacgga	actgtgagca	cgatgtgcgc	aaagagaact	gtgggtctgt	600
gccccatgac	acctggctgc	ccaagaagtg	tccctgtgt	aatatgcctggc	acggtcagct	660
ccgctgctt	cctcaggcat	ttctaccgg	ctgtgatggc	cttgcgtatgg	atgagcacct	720
cgtggcttcc	aggactccag	aactaccacc	gtctgcacgt	actaccactt	ttatgtctgt	780
tggcatctgc	ctttctatac	aaagctacta	ttaatcgaca	ttgacctatt	tccagaaaata	840
caattttaga	tatcatgcaa	atttcatgac	cagtaaaggc	tgctgctaca	atgtccctaac	900
tgaagatga	tcattttag	ttgccttaaa	ataatgaata	caatttccaa	aatggtctct	960
aacatttcct	tacagaacta	cttcttactt	ctttgccttg	ccctctccca	aaaaactact	1020
tcttttttca	aaagaaaatc	agccatatct	ccattgtgcc	taagttccagt	gtttcttttt	1080
ttttttttt	ttgagacgga	gtctcactct	gtcacccagg	ctggactgca	atgacgcgat	1140
cttggttcac	tgcaacccctc	gcattccgggg	ttcaagccat	tctccctgcct	aaggctccca	1200
agtaactggg	attacaggca	tgtgtcacca	tgcccagcta	atttttttgt	attttagtag	1260
agatgggggt	ttcaccat	tggccagtct	ggtctcgaaac	tctgacccctt	tgatccatcg	1320
atcagccctct	cgagtgtcga	gattcacac	gtgagcaact	gtgcaaggcc	ttgtgtttct	1380
tgatacatgt	aatttctacca	aggttttttt	aatatgttct	tttaaatgat	tgaattataat	1440
gttcagatta	ttggagacta	attttaatgt	ggaccttaga	atacagttt	gagtagagtt	1500
gatcaaaaato	aattaaaaata	gtctctttaa	aaggaaagaa	aacatcttta	aggggaggaa	1560
ccagagtgtct	gaaggaatgg	aagtccatct	gcgtgtgtc	agggagactg	ggttaggaaag	1620
agaagcaaa	tagaagagag	aggttggaaa	acaaaatggg	ttacttgatt	ggtgattagg	1680
tgtgtgtaga	gaagcaagta	aaaaggctaa	atggaaaggc	aagttccat	catctataga	1740
aagcttatata	agacaagaac	tccctttttt	ttcccaaagg	cattataaaa	agaatgaagc	1800
ctcccttagaa	aaaaaaattat	acctcaatgt	ccccaaacaag	attgcttaat	aaattgtgtt	1860
tccctccaagc	tattcaattc	ttttactgt	tgtagaagac	aaaatgttca	caatataattt	1920
agttgtaaac	caagtgtatca	aactacat	tgtaaagccc	atttttaaaa	tacattgtat	1980
atatgtgtat	gcacagtaaa	aatggaaact	atattgac	aaaaaaaaaa	aaa	2033